Linked Life Data

10734301

Source:http://linkedlifedata.com/resource/pubmed/id/10734301

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
6
pubmed:dateCreated
2000-5-18
pubmed:abstractText
We examined the incidence of herpes varicella-zoster virus (VZV) infection in 151 patients undergoing allogeneic BMT between August 1990 and September 1997 and who survived at least 3 months. Median follow-up was 17 (range 3.3-80.7) months. Herpes simplex virus antibody positive (HSV+) patients received aciclovir 1200 mg p.o. daily or 750 mg i.v. daily, in divided doses from day 0 to engraftment. Ganciclovir (5 mg/kg i.v. three times per week) was given in CMV+ patients (or if the donor was CMV+) from engraftment to day 84. Ganciclovir was continued or recommenced if a dose of greater than 20 mg of prednisone was used for the treatment of GVHD otherwise aciclovir was recommenced. In HSV+ patients not receiving ganciclovir, aciclovir 600 mg p.o. daily in divided doses was given until at least 6 months after BMT. Thirty-two patients developed VZV infection from 4.1 to 28 months after transplant. The estimated cumulative incidence of VZV was 13% (95% confidence interval 6-19%) at 12 months, 32% (22-42%) at 24 months and 38% (27-50%) at 28 months, with no further cases beyond that time. No patient developed VZV whilst receiving aciclovir or ganciclovir (P < 0.0001). However, there was a rapid onset of VZV following cessation of antiviral therapy (33% (20-46%) at 1 year post cessation). The presence of GVHD and the prior duration of antiviral prophylaxis were significant and independent risk factors for the development of VZV. Age, underlying disease, conditioning therapy or donor type were not. We conclude that 3-6 months of low-dose aciclovir and ganciclovir are effective at delaying the onset of VZV after allogeneic BMT, but may not affect the overall incidence of infection. Prolonged prophylaxis may be warranted in patients at high risk of infection, for example those patients with GVHD.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0268-3369
pubmed:author
pubmed:issnType
Print
pubmed:volume
25
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
657-64
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:10734301-2-Aminopurine, pubmed-meshheading:10734301-Acyclovir, pubmed-meshheading:10734301-Adolescent, pubmed-meshheading:10734301-Adult, pubmed-meshheading:10734301-Age of Onset, pubmed-meshheading:10734301-Aged, pubmed-meshheading:10734301-Analysis of Variance, pubmed-meshheading:10734301-Antiviral Agents, pubmed-meshheading:10734301-Bone Marrow Transplantation, pubmed-meshheading:10734301-Chickenpox, pubmed-meshheading:10734301-Dose-Response Relationship, Drug, pubmed-meshheading:10734301-Enzyme Activation, pubmed-meshheading:10734301-Female, pubmed-meshheading:10734301-Ganciclovir, pubmed-meshheading:10734301-Graft vs Host Disease, pubmed-meshheading:10734301-Herpes Zoster, pubmed-meshheading:10734301-Herpesvirus 3, Human, pubmed-meshheading:10734301-Humans, pubmed-meshheading:10734301-Incidence, pubmed-meshheading:10734301-Male, pubmed-meshheading:10734301-Middle Aged, pubmed-meshheading:10734301-Prodrugs, pubmed-meshheading:10734301-Retrospective Studies, pubmed-meshheading:10734301-Risk Factors, pubmed-meshheading:10734301-Skin Diseases, pubmed-meshheading:10734301-Transplantation, Homologous, pubmed-meshheading:10734301-Valine
pubmed:year
2000
pubmed:articleTitle
Varicella-zoster infection after allogeneic bone marrow transplantation: incidence, risk factors and prevention with low-dose aciclovir and ganciclovir.
pubmed:affiliation
Bone Marrow Transplant Service, Royal Melbourne Hospital, Melbourne, Australia.
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't